Literature DB >> 948031

Influence of inhibitors of prostaglandin synthesis on venoconstrictor responses to bradykinin.

M R Goldberg, B M Chapnick, P D Joiner, A L Hyman, P J Kadowitz.   

Abstract

The interrelationship between prostaglandins (PGs) and bradykinin (BK) was studied in isolated canine saphenous veins. The hypothesis that PGs mediate the venoconstrictor effect of bradykinin was evaluated by determining the influence of low concentrations of indomethacin (Indo) (1 muM) or eicosa-5,8,11,14-tetraynoic acid (ETA) (3 muM), two inhibitors of PG synthesis, on cumulative concentration-response curves for BK or norepinephrine (NE). In the tissue bath, responses to BK improved with time while responses to NE did not vary. When strips were least responsive to BK, Indo and ETA enhanced these responses. When strips were most responsive to BK, neither inhibitor enhanced the responses. Neither Indo nor ETA altered responses to NE. Phentolamine (10(-8) M) did not alter responses to BK. These data suggest that endogenous PGs act to attenuate, rather than mediate, the venoconstrictor response to BK. Progressive enhancement of responses to BK of untreated saphenous vein strips is associated with a decreased ability of inhibitors of PG synthesis to enhance those responses also. Thus, there may be a time-related decrease in the ability of this preparation to synthesize PGs. From the present results, it cannot be determined whether saphenous veins in vivo are highly responsive or relatively unresponsive to the peptide. However, these data do suggest that PGs are a determinant of venous responsiveness to BK.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 948031

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Involvement of capsaicin-sensitive neurones in the haemodynamic effects of exogenous vasoactive peptides: studies in conscious, adult Long Evans rats treated neonatally with capsaicin.

Authors:  H Bachelard; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  A comparison of bradykinin- and capsaicin-induced myocardial and coronary effects in isolated perfused heart of guinea-pig: involvement of substance P and calcitonin gene-related peptide release.

Authors:  S Manzini; F Perretti; L De Benedetti; P Pradelles; C A Maggi; P Geppetti
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

3.  The bradykinin-induced coronary vasodilation. Evidence for an additional prostacyclin-independent mechanism.

Authors:  K Schrör; U Metz; R Krebs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

4.  Role of calcium in prostaglandin E release induced by bradykinin and the ionophore A 23187.

Authors:  H Juan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-06       Impact factor: 3.000

5.  Mechanism of action of bradykinin-induced release of prostaglandin E.

Authors:  H Juan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

6.  Demonstration of extrapulmonary activity of angiotensin converting enzyme in intact tissue preparations.

Authors:  F Lembeck; T Griesbacher; M Eckhardt
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

7.  Effect of bradykinin antagonists on bradykinin-induced plasma extravasation, venoconstriction, prostaglandin E2 release, nociceptor stimulation and contraction of the iris sphincter muscle in the rabbit.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

8.  Decreases in histamine forming enzyme activity of non-metastasizing fibrosarcomas in hamsters with progressive tumor growth.

Authors:  T C Moore; L E Koppelman; C A Lemmi
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

9.  Interaction of cyclosporine-A with the renin-angiotensin system in canine veins.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-08       Impact factor: 3.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.